High-dose melphalan with autotransplantation for refractory multiple myeloma: Results of a Southwest Oncology Group phase II trial

Journal of Clinical Oncology

Volumn 17, Issue 7, 1999, Pages 2173-2179

  Vesole, David H ^a   Crowley, John J ^a   Catchatourian, Rose ^a   Stiff, Patrick J ^a   Johnson, David B ^a   Cromer, Jeana ^a   Salmon, Sydney E ^a   Barlogie, Bart ^a  

^a SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MELPHALAN;

ADULT; AGED; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0033023217     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.7.2173     Document Type: Article

References (35)

1. Barlogie B, Epstein J, Selvanayagam, et al: Plasma cell myeloma: New biological insights and advances in therapy. Blood 73:865-869, 1989
2. Bergsagel DE, Sprague CC, Austin C, et al: Evaluation of new chemotherapeutic agents in the treatment of multiple myeloma: IV. L-Phenylalanine mustard. Cancer Chemother Rep 21:87-99, 1962
3. Kyle RA: Diagnosis and management of multiple myeloma and related disorders. Prog Hematol 14:257-282, 1996
4. Buzaid AC, Durie BG: Management of refractory multiple myeloma: A review. J Clin Oncol 6:889-905, 1988
5. Barlogie B, Smith L, Alexanian R: Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 310:1353-1356, 1984
6. Alexanian R, Barlogie B, Dixon D: High dose glucocorticoid treatment for resistant multiple myeloma. Ann Intern Med 105:8-11, 1986
7. McElwain TJ, Powles RL: High-dose intravenous melphalan for plasma-cell leukemia and myeloma. Lancet 1:822-823, 1993
8. Barlogie B, Alexanian R, Dicke K, et al: High dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 70:869-872, 1987
9. Barlogie B, Jagannath S, Dixon D, et al: High-dose melphalan and GM-CSF for refractory multiple myeloma. Blood 76:677-680, 1990
10. Fermand JP, Levy Y, Gerota J, et al: Treatment of aggressive multiple myeloma by high-dose chemotherpay and total body irradiation followed by blood stem cell autologous graft. Blood 73:20-23, 1989
11. Ventura GJ, Barlogie B, Hester JP, et al: High dose cyclophosphamide, BCNU and VP-16 with autologous stem cell support for refractory multiple myeloma. Bone Marrow Transplant 5:265-268, 1990
12. Vesole DH, Barlogie B, Jagannath S, et al: High-dose therapy for refractory multiple myeloma: Improved prognosis with better support care and double transplants. Blood 84:950-956, 1994
13. Jagannath S, Vesole DH, Glenn L, et al: Low risk intensive therapy for multiple myeloma with combined autologous bone marrow and blood stem cell support. Blood 80:1666-1672, 1992
14. Attal M, Harousseau JL, Stoppa A-M, et al: A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 335:91-97, 1996
15. Harousseau JL, Attal M, Divine M, et al: Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: A report of the French Registry on autologous transplantation in multiple myeloma. Blood 85:3077-3085, 1995
16. Cunningham D, Paz-Ares L, Milan S, et al: High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 12:759-763, 1994
17. Vesole DH, Tricot G, Jagannath S, et al: Autotransplants in multiple myeloma: What have we learned? Blood 88:838-847, 1996
18. Barlogie B, Jagannath S, Desikan KR, et al: Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 93:55-65, 1999
19. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
20. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
21. Alexanian R, Dimopolous MA, Hester J, et al: Early myeloablative therapy for multiple myeloma. Blood 84:4278-4282, 1994
22. Alexanian R, Dimopolous M, Smith L, et al: Limited value of myeloablative therapy for late multiple myeloma. Blood 83:512-516, 1994
23. Dimopoulos MA, Alexanian R, Przepiorka D, et al: Thiotepa, busulfan, and cyclophosphamide: A new preparative regimen for autologous marrow or blood stem cell transplantation in high-risk multiple myeloma. Blood 82:2324-2328, 1993
24. Stuckey WJ, Crowley J, Baker LH, et al: Phase II trial of diaziquone in patients with refractory and relapsing multiple myeloma: A Southwest Oncology Group study. Cancer Treat Rep 71:1095-1096, 1987
25. Karanes C, Crowley J, Sawkar L, et al: Aclacinomycin A in the treatment of multiple myeloma: A Southwest Oncology Group study. Invest New Drugs 8:101-104, 1990
26. Grever MR, Crowley J, Salmon S, et al: Phase II investigation of pentostatin in multiple myeloma: A Southwest Oncology Group study. J Natl Cancer Inst 82:1778-1779, 1990
27. Hanson KH, Crowley J, Salmon SE, et al: Evaluation of amonafide in refractory and relapsing multiple myeloma: A Southwest Oncology Group study. Anticancer Drugs 2:247-250, 1991
28. Durie BG, Crowley J, Coltman CA, et al: Phase II evaluation of bisantrene in refractory multiple myeloma: A Southwest Oncology Group study. Invest New Drugs 9:329-331, 1991
29. Barlogie B, Crowley J, Salmon SE, et al: Phase II study of carboplatin (CBDCA) in refractory multiple myeloma: A Southwest Oncology Group study. Invest New Drugs 12:53-55, 1994
30. Gupta V, Thompson EB, Stock-Novack D, et al: Efficacy of prednisone in refractory myeloma and measurement of glucocorticoid receptors: A Southwest Oncology Group study. Invest New Drugs 12:121-128, 1994
31. Kraut EH, Crowley JJ, Wade JL, et al: Evaluation of topotecan in resistant and relapsing multiple myeloma: A Southwest Oncology Group study. J Clin Oncol 16:589-592, 1998
32. Desikan K, Barlogie B, Jagannath S, et al: Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma patients. J Clin Oncol 16:1547-1553, 1998
33. Schiller G, Vescio R, Freytes C, et al: Transplantation of CD34+ peripheral blood progenitor cells after high-dose chemotherapy for patients with advanced multiple myeloma. Blood 86:390-397, 1995
34. Gazitt Y, Reading CC, Hoffman R, et al: Purified CD34+Lin-Thy+ stem cells do not contain clonal myeloma cells. Blood 86:381-389, 1995
35. Gazitt Y, Barlogie B, Tian E, et al: Double autotransplants can induce molecular remission in newly diagnosed patients with multiple myeloma. Proc Am Assoc Cancer Res 37:1315a, 1996 (abstr)